The trial consists of a modified 3+3 dose-escalation design in Part 1 to establish the maximum tolerated dose (MTD) of SON-1010 with a fixed dose of atezolizumab. 

Clinical benefit in PROC will be confirmed in an expansion group to establish the recommended Phase 2 dose (RP2D). 

Part 2 of the study will then investigate SON-1010 monotherapy, its use in combination with atezolizumab, or the standard of care (SOC) for PROC in a randomized comparison to show proof-of-concept.

SB221 is a global Phase 1b/2a multicenter, dose-escalation and randomized POC study to assess the safety, tolerability, PK, PD, and efficacy of SON-1010 administered subcutaneously (SC), either alone or in combination with atezolizumab given intravenously (IV). 

Price Action: SONN shares are up 23.78% at $0.40 at publication Wednesday.

Read Next: Why Performance Food Shares Are Gaining Today